Clinical Trials Sponsored by Shanghai JMT-Bio Inc.

Total 24 results

Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (mCRC)
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Glucocorticoid Induced Osteoporosis

China
Shanghai JMT-Bio Inc.

Completed

A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
Shanghai JMT-Bio Inc.

Active, not recruiting

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Local Advanced or Metastatic NSCLC | Harboring EGFR Common Mutation

China
Shanghai JMT-Bio Inc.

Completed

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Shanghai JMT-Bio Inc.

Active, not recruiting

Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.

Recruiting

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Stomach Cancer

China
Shanghai JMT-Bio Inc.

Recruiting

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

China
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Shanghai JMT-Bio Inc.
Quintiles, Inc.; Covance; KingMed Diagnostics

Unknown

Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors (JMT103)

Bone Metastases

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

Hypercalcemia of Malignancy
Hengenix Biotech Inc
Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ Bio-Tech Co., Ltd

Withdrawn

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

COVID 19
Shanghai Henlius Biotech
Hengenix Biotech Inc; Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ...

Withdrawn

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

COVID-19
Shanghai Bio-heart Biological Technology Co., Ltd.
CCRF Inc., Beijing, China

Active, not recruiting

Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Coronary Artery Disease | Antineoplastic Agents

China
Shanghai Bio-heart Biological Technology Co., Ltd.
CCRF Inc., Beijing, China

Not yet recruiting

A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

Coronary Artery Disease

China

Clinical Trials Sponsored by Shanghai JMT-Bio Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations